Cannabis company Aurora Cannabis Inc ACB reported Monday with its first full-quarter results, which showed that the company held a 20-percent market share of recreational volumes in 2018, according to Canaccord Genuity.
The Analyst
Analyst Matt Bottomley maintains a Speculative Buy rating on Aurora with an unchanged CA$13 ($9.80) price target on the Canadian-listed equity.
The Thesis
Aurora's Q2 report was highlighted by revenue of CA$54.2 million, near the high end of management's own guidance range and inline with expectations, Bottomley said in a Tuesday note.
Sales of recreational cannabis totaled CA$21.6 million, which gives the company the second-highest market share in the Canadian recreational space, the analyst said. This solidifies strong execution from management at a time when many producers went through logistical supply chain problems, he said.
Aurora achieved an estimated gross price of less than CA$6 per gram of dried bud and less than CA$10 per equivalent gram of oil in the quarter — both of which were better than expected, Bottomley said.
The company is in the process of integrating multiple new platforms as a result of acquisitions made over the past few quarters, including MedReleaf and Anandia Labs. Investors should be paying close attention to signs of success in integrating the acquired properties over the next few quarters, according to Canaccord.
Price Action
Aurora Cannabis shares were up 3.14 percent at $7.39 at the time of publication Tuesday.
Related Links:
Why Analysts Are Excited About These Three Cannabis Stocks
States Push To Expand Cannabis Access: Will The Market Follow?
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.